Hospital-acquired infections, also known as nosocomial infections, are acquired by patients in the hospitals or healthcare facilities. Urinary tract infections, bloodstream infections, surgical-site infections, Clostridium difficile associated diarrhea, and pneumonia are examples of nosocomial infections.
The hospital infection therapeutics market is increasing at a significant rate, due to high susceptibility of neonatal population in healthcare setting and high occurrence of numerous hospital infections. Increasing incidences of hospital infections, high number of pipeline drug molecules for specific treatment of healthcare associated infections and high unaddressed needs in most of the countries are some of the factors providing ample opportunities for the hospital infection therapeutics market to grow in the coming years.

Market Analysis and Insights: Global Hospital Infection Therapeutics Market
The global Hospital Infection Therapeutics market size is projected to reach US$ 3240.4 million by 2027, from US$ 2724.5 million in 2020, at a CAGR of 2.5% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Hospital Infection Therapeutics market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Hospital Infection Therapeutics market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Hospital Infection Therapeutics market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Hospital Infection Therapeutics market.

Global Hospital Infection Therapeutics Scope and Market Size
Hospital Infection Therapeutics market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Hospital Infection Therapeutics market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
Antibacterial Drugs
Antiviral Drugs
Antifungal Drugs

Segment by Application
Hospital Acquired Pneumonia
Surgical Site Infections
Urinary Tract Infection
Gastrointestinal Disorders
Bloodstream Infections
Others

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
Bayer
Johnson & Johnson Services
Actavis
Sanofi
Bristol Myers Squibb Company
AstraZeneca
Pfizer
Merck
GlaxoSmithkline
Cubist Pharmaceuticals